Enanta Pharmaceuticals to Join Jefferies Global Healthcare Conference

Enanta Pharmaceuticals, Inc., a biotechnology firm listed on NASDAQ under the ticker symbol ENTA, announced its participation in the Jefferies Global Healthcare Conference. This event, slated for June 5, 2024, will feature a fireside chat involving key company leaders, including President and CEO Jay R. Luly, Ph.D., and Chief Product Strategy Officer Tara L. Kieffer, Ph.D. The session is scheduled to begin at 7:30 a.m. Eastern Time in New York, NY.

For those interested in the live webcast of the event, it can be accessed through the "Events and Presentations" section on the "Investors" page of Enanta's website. Following the live presentation, a replay of the webcast will be available and archived for at least 30 days, allowing stakeholders ample opportunity to catch up on the discussions.

Enanta Pharmaceuticals is a clinical-stage biotechnology company with a strong emphasis on developing small molecule drugs aimed at treating various virology and immunology conditions. The company's approach is heavily driven by robust chemistry and drug discovery capabilities. Currently, Enanta's research and development efforts are focusing on diseases such as respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). In the past, the company has also developed clinical-stage compounds targeting SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infections.

One of Enanta's significant accomplishments is the discovery of glecaprevir, a protease inhibitor that has become a cornerstone in the treatment regimen for chronic hepatitis C virus (HCV) infection. This drug is marketed by AbbVie under the brand names MAVYRET® in the United States and MAVIRET® outside the United States, in combination with pibrentasvir. The success of these HCV treatment products has resulted in ongoing royalty payments to Enanta, providing a steady stream of funding that supports the company's ongoing operations and research initiatives.

In summary, Enanta Pharmaceuticals continues to make substantial strides in the biotechnology sector, particularly in the areas of virology and immunology. Their participation in the Jefferies Global Healthcare Conference underscores their commitment to engaging with the broader healthcare community and sharing their progress and future plans. With a focus on innovative drug discovery and development, Enanta is well-positioned to contribute significantly to the treatment of challenging viral and immune-related diseases.